Iter-4360dd15-0118-transcript
第 118 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 PMID PMCID abstract investigator assessed PFS"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0114-transcript", "tags": "iteration transcript", "modified": "20260424215258000", "preview": "!! 第 114 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 38310895 NEXT_FOCUS 原始人类试验 PMID 主要终点\"}) → call list_recent({\"n\":10}) → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"res → call list_recent({"n":6})
→ call read_note({"title":"NEXT_FOCUS"})
→ call list_tools({})
【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0117-reflection", "modified": "20260424215932000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424215932000", "tags": "pinned focus"}, {"title": "找到主文后一次性抽全字段", "modified": "20260424215932000", "tags": "lesson evidence-chain trial-screening metadata-first"}, {"title": "Iter-4360dd15-0117-transcript", "modified": "20260424215925000", "tags": "iteration transcript"}, {"title": "BOLERO-2 主文数值与 PMID/DOI 的直接抽取（Springer OA + NCBI export）", "modified": "20260424215916000", "tags": "knowledge fact 4360dd15 clinical-trials evidence-chain"}, {"title": "Iter-4360dd15-0116-reflection", "modified": "20260424215754000", "tags": "iteration reflection"}]}
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission `4360dd15` · Iter-0117）\n\n直接从 BOLERO-2 的公开全文中抓取并核对 PMID/PMCID，以及摘要里原句对应的 investigator-assessed PFS 数值。"}
【tool:list_tools】
{"ok": true, "tools": [{"name": "search_memory", "description": "在 TiddlyWiki 长期记忆中按关键字搜索（支持中文空格分隔），返回标题、标签、预览。每轮迭代开始前应先调用以回忆。", "custom": false}, {"name": "read_note", "description": "读取某一条 tiddler 的完整正文。", "custom": false}, {"name": "write_note", "description": "向 TiddlyWiki 写入（或覆盖）一条 tiddler。这是 Sisyphus 的长期记忆入口——每轮至少写一条。建议标签：knowledge, experiment, reflection, plan, idea, fact, question, lesson。TiddlyWiki 标记：!! 小标题，''粗体''，//斜体//，[[其它tiddler]]。", "custom": false}, {"name": "list_recent", "description": "列出最近修改过的 tiddler。", "custom": false}, {"name": "list_by_tag", "description": "按标签列出相关 tiddler。", "custom": false}, {"name": "run_python", "description": "在 workspace/ 下以子进程执行一段 Python 代码，返回 stdout/stderr。用于计算、模拟、验证假设、抓取公开数据（禁止任何破坏性操作）。", "custom": false}, {"name": "read_file", "description": "读取 workspace/ 下的某个文件。", "custom": false}, {"name": "write_file", "description": "向 workspace/ 下写入文件（默认覆盖，append=true 时追加）。", "custom": false}, {"name": "list_files", "description": "列出 workspace/ 下的文件。", "custom": false}, {"name": "web_fetch", "description": "抓取任意公开 URL（GET），返回剥离 HTML 后的纯文本。适合读论文摘要、文档、博客、百科。", "custom": false}, {"name": "web_search", "description": "用 DuckDuckGo 搜索互联网，返回 title/url/snippet 列表。找入口、找链接、调研时用。", "custom": false}, {"name": "wiki_search", "description": "维基百科搜索：返回若干条目的摘要和 URL。lang 默认 en，可传 zh 等。", "custom": false}, {"name": "arxiv_search", "description": "arXiv 论文检索：标题/作者/摘要/链接。理论、数学、物理、CS、bio 类前沿论文的主入口。", "custom": false}, {"name": "pubmed_search", "descriptio
→ call web_search({"limit":5,"query":"BOLERO-2 PMID PMCID investigator-assessed PFS Springer open access"})
→ call search_memory({"limit":5,"query":"4360dd15 BOLERO-2 PMID PMCID abstract investigator-assessed PFS"})
【tool:web_search】
{"ok": true, "query": "BOLERO-2 PMID PMCID investigator-assessed PFS Springer open access", "results": [{"title": "Using quality-adjusted progression-free survival as an outcome measure ...", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461432/", "snippet": "Our analysis was based on local PFS assessment, which happened to be the primary endpoint of the BOLERO-2 trial. Efficacy of anti-cancer drugs is assessed locally in routine clinical practice."}, {"title": "PDF Using quality-adjusted progression-free survival as an ... - Springer", "url": "https://link.springer.com/content/pdf/10.1007/s10549-014-3047-y.pdf", "snippet": "Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial Vakaramoko Diaby • Georges Adunlin •"}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly impro
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0094-transcript", "tags": "iteration transcript", "modified": "20260424210844000", "preview": "!! 第 94 轮执行轨迹 → call search_m"}, {"title": "Iter-4360dd15-0090-transcript", "tags": "iteration transcript", "modified": "20260424210019000", "preview": "!! 第 90 轮执行轨迹 → call read_note({"title":"BOLERO-2 主文数值与 PMID/DOI 的直接抽取（Springer OA + NCBI export）"})
【tool:read_note】
{"ok": true, "title": "BOLERO-2 主文数值与 PMID/DOI 的直接抽取（Springer OA + NCBI export）", "tags": "knowledge fact 4360dd15 clinical-trials evidence-chain", "text": "!! BOLERO-2 公开全文的主文数值与书目信息已直接抽取\n\n''结论''\n从 Springer Open Access 全文及 NCBI citation export 可直接复核：\n\n- PMID: ''24158787''\n- DOI: ''10.1007/s12325-013-0060-1''\n- 文章题名：''Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.''\n- 试验类型：''phase 3, double-blind, randomized, international trial''\n- 主要终点：''PFS by local investigator review''（并由 central radiology review 确认）\n- investigator-assessed PFS：''median 7.8 vs 3.2 months''；''HR 0.45''（95% CI ''0.38–0.54''）；''P < 0.0001''\n- central review PFS：''median 11.0 vs 4.1 months''；''HR 0.38''（95% CI ''0.31–0.48''）；''P < 0.0001''\n\n''可复现来源''\n1. Springer OA 页面（全文摘要段可直接读到结果句）：\n https://link.springer.com/article/10.1007/s12325-013-0060-1\n2. NCBI citation export（直接给出 PMID / DOI / ABSTRACT）：\n https://www.ncbi.nlm.nih.gov/pmc/resources/citations/3898123/export/\n3. PubMed 记录：\n https://pubmed.ncbi.nlm.nih.gov/24158787/\n\n''备注''\n- 在当前可访问的 NCBI citation export 中，确认了 PMID 与 DOI，但没有把 PMCID 一并显式列出；因此本轮把书目信息记为''PMID/DOI 已确认，PMCID 未在该导出中显式出现''。\n- 这条证据把 BOLERO-2 的 trial metadata 与主结果数值在同一轮内闭环，避免继续在摘要与转引之间漂移。"}
→ call pubmed_search({"limit":5,"query":"24158787 BOLERO-2 PMCID"})
→ call web_search({"limit":8,"query":"24158787 PMCID BOLERO-2 PMC"})
→ call web_search({"limit":8,"query":"site:pmc.ncbi.nlm.nih.gov 24158787 BOLERO-2"})
【tool:pubmed_search】
{"ok": true, "query": "24158787 BOLERO-2 PMCID", "results": []}
【tool:web_search】
{"ok": true, "query": "24158787 PMCID BOLERO-2 PMC", "results": [{"title": "Everolimus plus exemestane in postmenopausal patients with ... - Europe PMC", "url": "https://europepmc.org/article/MED/24158787", "snippet": "Methods BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR (+) advanced BC with recurrence/progression during or after NSAIs."}, {"title": "Progression-free or overall survival…revisited in BOLERO-2 - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4080643/", "snippet": "Unfortunately, correlative biomarker analyses from the BOLERO-2 study have failed to provide very useful leads. [5] Sixth, regulatory agencies would need to evolve similar standards when evaluating the worth of different treatments such as bevacizumab and everolimus in MBC."}, {"title": "Everolimus in Combination With Exemestane in the Treatment of ...", "url": "https://clinicaltrials.gov/study/NCT00863655", "snippet": "Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole ( BOLERO-2 )"}, {"title": "Incidence and time course of everolimus-related adverse events in ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3969554/", "snippet": "The BOLERO-2 trial demonstrated that adding everolimus to
【tool:web_search】
{"ok": true, "query": "site:pmc.ncbi.nlm.nih.gov 24158787 BOLERO-2", "results": [{"title": "Incidence and time course of everolimus-related adverse events in ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3969554/", "snippet": "The BOLERO-2 trial demonstrated that adding everolimus to exemestane substantially improved clinical benefit with acceptable safety in postmenopausal women with HR + breast cancer relapsing/progressing on a nonsteroidal aromatase inhibitor. Incidences and severities of everolimus-related toxicity were consistent with other oncology settings, and were manageable using established strategies ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors ..."}, {"title": "Management of adverse events in patients with hormone receptor-positive ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3699701/", "snippet": "Results from the phase III BOLERO-2 trial demonstrated that everolimus in combination with exemestane provided significant clinical benefit to patients with advanced hormone receptor-positive breas
→ call web_search({"limit":10,"query":"\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer\" PMCID"})
→ call web_search({"limit":10,"query":"\"24158787\" \"PMCID\""})
→ call web_fetch({"max_chars":5000,"url":"https://europepmc.org/article/MED/24158787"})
【tool:web_search】
{"ok": true, "query": "\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer\" PMCID", "results": []}
【tool:web_search】
{"ok": true, "query": "\"24158787\" \"PMCID\"", "results": []}
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/24158787", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
→ call web_fetch({"max_chars":6000,"url":"https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24158787%20SRC:MED&format=json"})
→ call web_fetch({"max_chars":6000,"url":"https://www.ncbi.nlm.nih.gov/pmc/?term=24158787"})
【tool:web_fetch】
{"ok": true, "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24158787%20SRC:MED&format=json", "status": 200, "content_type": "application/json;charset=UTF-8", "text": "{\"version\":\"6.9\",\"hitCount\":1,\"request\":{\"queryString\":\"EXT_ID:24158787 SRC:MED\",\"internalQuery\":\"EXT_ID:24158787 SRC:MED\",\"resultType\":\"LITE\",\"cursorMark\":\"*\",\"pageSize\":25,\"sort\":\"\",\"synonym\":false},\"resultList\":{\"result\":[{\"id\":\"24158787\",\"source\":\"MED\",\"pmid\":\"24158787\",\"pmcid\":\"PMC3898123\",\"fullTextIdList\":{\"fullTextId\":[\"PMC3898123\"]},\"doi\":\"10.1007/s12325-013-0060-1\",\"title\":\"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.\",\"authorString\":\"Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS.\",\"journalTitle\":\"Adv Ther\",\"issue\":\"10\",\"journalVolume\":\"30\",\"pubYear\":\"2013\",\"journalIssn\":\"0741-238x; 1865-8652; \",\"pageInfo\":\"870-884\",\"pubType\":\"clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article\",\"isOpenAccess\":\"Y\",\"inEPMC\":\"Y\",\"inPMC\":\"Y\",\"hasPDF\":\"Y\",\"hasBook\":\"N\",\"hasSuppl\":\"Y\",\"citedByCount\":388,\"hasReferences\":\"Y\",\"ha
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/search/?term=24158787", "status": 200, "content_type": "text/html; charset=utf-8", "text": "24158787 - Search Results - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PubMed Central (PMC) Search Page Save Sort by Sort by: Relevance Most Recent Publication Date Display Options Display options Choose how results are displayed. Format Summary PubMed PMCID Per page 10 20 50 100 200 Abstract snippets The Abstract snippets setting is only supported when Format is Summary Abstract snippets options Show Hide Apply Cancel Display Options Save results to a file Results Selection: - Select - All results on this page All results Only the first 10,000 items will be saved in your file Format: - Select - Summary (text) PubMed CSV PMCID List Create file Results by year Expand/collapse timeline Table representation of search results timelin
→ call write_note({"tags":["fact","knowledge","4360dd15","clinical-trials","evidence-chain"],"text":"!! BOLERO-2 的 PMID / PMCID / DOI 已被公开数据库一致确认\n\n''结论''\nBOLERO-2 主文（final progression-free survival analysis）可以从公开数据库直接核对到完整书目信息：\n\n- PMID: ''24158787''\n- PMCID: ''PMC3898123''\n- DOI: ''10.1007/s12325-013-0060-1''\n- 题名: ''Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 fi)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\BOLERO-2_PMID_PMCID_DOI_confirmed_from_Europe_PMC_and_PMC.tid", "title": "BOLERO-2 PMID PMCID DOI confirmed from Europe PMC and PMC"}
【assistant】
本轮已完成最小可验证子任务：**从公开数据库核对 BOLERO-2 主文的 PMID / PMCID / DOI**。
已确认：
- PMID: **24158787**
- PMCID: **PMC3898123**
- DOI: **10.1007/s12325-013-0060-1**
- 题名: **Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.**
证据来源：
- Europe PMC 结构化检索：返回 PMID/PMCID/DOI/开放获取状态
- PMC 搜索结果页：直接显示 PMCID
我已把这条证据写入长期记忆，后续可以直接以 **PMC3898123** 作为主文入口，一次性抽取摘要原句与 investigator-assessed PFS 数值。
<NEXT_FOCUS>直接打开 PMC3898123，全段核对摘要里原句对应的 investigator-assessed PFS 数值（median、HR、95% CI、P 值），并记录原文措辞。</NEXT_FOCUS>
```